DMT, a fast-acting psychedelic also taken as the plant brew ayahuasca, is studied for depression. One supported session gave a quick, sometimes lasting mood lift in small placebo-compared trials. Evidence for other benefits is weaker; longevity claims rest on animal or cell studies. Main risks are brief blood pressure surges, vomiting, and intense fear; rarer serious harms cluster in psychotic or bipolar histories, risky drug combinations, and unsupervised use. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure | <120/80 mmHg | Acute surge risk |
| Resting heart rate | 50–70 bpm | Acute surge risk |
| QTc on electrocardiogram | <430 ms (men), <450 ms (women) | Rhythm safety |
| High-sensitivity C-reactive protein (hs-CRP) | <1.0 mg/L | Inflammation trend |
| PHQ-9 depression score | 0–4 | Track mood response |
| C-SSRS suicide screen | No ideation or behavior | Safety check |
Cadence: Vital signs before dosing and every 5–15 minutes until effects resolve; symptom questionnaires at 1 day, 1 week, 2 weeks, 1 month, and 3 months; optional hs-CRP repeated at 1 and 3 months